Table 4. Sensitivity Analysis.
Hazard Ratio (95% CI) for first VF after sustained viral suppression >6 months (n = 14,389 / 6,295 failures).
| Medication Exposure Mode | Bias Correction | Statins | Non-Statin Lipid—lowering Agents | Antihyper-tensives | Cardiac Aspirin | |
|---|---|---|---|---|---|---|
| PDC (30/90d)* | None | 0.65 (0.60–0.70) | 0.74 (0.67–0.82) | 0.80 (0.75–0.84) | 0.88 (0.80–0.97) | |
| p<0.001 | p<0.001 | p<0.001 | p = 0.01 | |||
| Multivariate Adjustment | 0.91 (0.83–0.99) | 1.01 (0.90–1.12) | 1.00 (0.94–1.06) | 1.13 (1.02–1.25) | ||
| p = 0.04 | p = 0.9 | p = 0.98 | p = 0.02 | |||
| Current Use (within 7 d) | None | 0.67 (0.62–0.72) | 0.75 (0.68–0.82) | 0.83 (0.78–0.87) | 0.91 (0.83–1.00) | |
| p<0.001 | p<0.001 | p<0.001 | p = 0.04 | |||
| Multivariate Adjustment | 0.89 (0.82–0.97) | 0.95 (0.86–1.05) | 1.00 (0.94–1.06) | 1.12 (1.02–1.24) | ||
| p = 0.007 | p = 0.32 | p = 0.97 | p = 0.02 | |||
| IPW | Truncation | |||||
| <5% / >95% | 0.85 (0.78–0.94) | 0.90 (0.79–1.02) | 0.99 (0.93–1.05) | 1.04 (0.92–1.17) | ||
| p<0.001 | p = 0.10 | p = 0.69 | p = 0.57 | |||
| <1% / >99% | 0.93 (0.84–1.03) | 0.95 (0.83–1.10) | 1.02 (0.96–1.09) | 1.06 (0.93–1.21) | ||
| p = 0.18 | p = 0.51 | p = 0.46 | p = 0.40 | |||
| <0.1%/>99.9% | 1.00 (0.88–1.13) | 0.97 (0.84–1.13) | 1.04 (0.97–1.11) | 1.07 (0.93–1.23) | ||
| p = 0.97 | p = 0.73 | p = 0.24 | p = 0.32 | |||
All hazard ratios (HR) are followed by 95% confidence intervals in parenthesis. PDC: percentage of days covered, IPW: Inverse Probability Weighting for treatment and censoring.
*PDC interval 30 days for statins/CVMs and 90 days for ARVs. In PDC mode, HR is for 100% use.